Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.84
ICCC's Cash to Debt is ranked higher than
63% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. ICCC: 4.84 )
ICCC' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: 4.84

Equity to Asset 0.86
ICCC's Equity to Asset is ranked higher than
89% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. ICCC: 0.86 )
ICCC' s 10-Year Equity to Asset Range
Min: 0.59   Max: 0.97
Current: 0.86

0.59
0.97
F-Score: 8
Z-Score: 6.56
M-Score: -2.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -0.33
ICCC's Operating margin (%) is ranked higher than
67% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ICCC: -0.33 )
ICCC' s 10-Year Operating margin (%) Range
Min: -25.21   Max: 18.82
Current: -0.33

-25.21
18.82
Net-margin (%) 1.95
ICCC's Net-margin (%) is ranked higher than
70% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ICCC: 1.95 )
ICCC' s 10-Year Net-margin (%) Range
Min: -10.12   Max: 39.43
Current: 1.95

-10.12
39.43
ROE (%) 1.25
ICCC's ROE (%) is ranked higher than
66% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ICCC: 1.25 )
ICCC' s 10-Year ROE (%) Range
Min: -5.26   Max: 40.12
Current: 1.25

-5.26
40.12
ROA (%) 1.07
ICCC's ROA (%) is ranked higher than
69% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. ICCC: 1.07 )
ICCC' s 10-Year ROA (%) Range
Min: -4.63   Max: 34.48
Current: 1.07

-4.63
34.48
ROC (Joel Greenblatt) (%) -0.49
ICCC's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ICCC: -0.49 )
ICCC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -28.31   Max: 51.51
Current: -0.49

-28.31
51.51
Revenue Growth (%) 9.60
ICCC's Revenue Growth (%) is ranked higher than
80% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. ICCC: 9.60 )
ICCC' s 10-Year Revenue Growth (%) Range
Min: -19.3   Max: 17
Current: 9.6

-19.3
17
» ICCC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ICCC Guru Trades in

Q2 2013

ICCC Guru Trades in Q2 2013

Jim Simons 10,000 sh (New)
» More
Q3 2013

ICCC Guru Trades in Q3 2013

Jim Simons 11,000 sh (+10%)
» More
Q4 2013

ICCC Guru Trades in Q4 2013

Jim Simons 12,400 sh (+12.73%)
» More
» Details

Insider Trades

Latest Guru Trades with ICCC



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 113.80
ICCC's P/E(ttm) is ranked lower than
78% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. ICCC: 113.80 )
ICCC' s 10-Year P/E(ttm) Range
Min: 5.45   Max: 183.33
Current: 113.8

5.45
183.33
P/B 1.50
ICCC's P/B is ranked higher than
88% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ICCC: 1.50 )
ICCC' s 10-Year P/B Range
Min: 0.41   Max: 2.77
Current: 1.5

0.41
2.77
P/S 2.30
ICCC's P/S is ranked higher than
66% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. ICCC: 2.30 )
ICCC' s 10-Year P/S Range
Min: 0.87   Max: 6.06
Current: 2.3

0.87
6.06
PFCF 28.40
ICCC's PFCF is ranked lower than
61% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. ICCC: 28.40 )
ICCC' s 10-Year PFCF Range
Min: 2.72   Max: 600
Current: 28.4

2.72
600
EV-to-EBIT 47.60
ICCC's EV-to-EBIT is ranked lower than
71% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. ICCC: 47.60 )
ICCC' s 10-Year EV-to-EBIT Range
Min: 5.1   Max: 172.4
Current: 47.6

5.1
172.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
ICCC's Price/Net Cash is ranked higher than
89% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. ICCC: 3.70 )
ICCC' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 82.3
Current: 3.7

1.05
82.3
Price/Net Current Asset Value 2.90
ICCC's Price/Net Current Asset Value is ranked higher than
89% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. ICCC: 2.90 )
ICCC' s 10-Year Price/Net Current Asset Value Range
Min: 0.86   Max: 19.79
Current: 2.9

0.86
19.79
Price/Tangible Book 1.50
ICCC's Price/Tangible Book is ranked higher than
91% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ICCC: 1.50 )
ICCC' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 4.17
Current: 1.5

0.5
4.17
Price/DCF (Projected) 2.80
ICCC's Price/DCF (Projected) is ranked lower than
61% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ICCC: 2.80 )
ICCC' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 6.84
Current: 2.8

0.48
6.84
Price/Median PS Value 0.90
ICCC's Price/Median PS Value is ranked higher than
77% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ICCC: 0.90 )
ICCC' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 2.16
Current: 0.9

0.28
2.16
Price/Graham Number 2.80
ICCC's Price/Graham Number is ranked lower than
58% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ICCC: 2.80 )
ICCC' s 10-Year Price/Graham Number Range
Min: 0.25   Max: 4.29
Current: 2.8

0.25
4.29
Earnings Yield (Greenblatt) 2.10
ICCC's Earnings Yield (Greenblatt) is ranked lower than
59% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. ICCC: 2.10 )
ICCC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 19.7
Current: 2.1

0.6
19.7
Forward Rate of Return (Yacktman) -4.07
ICCC's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. ICCC: -4.07 )
ICCC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: 110.9
Current: -4.07

-8.1
110.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
ImmuCell Corporation was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987. It completed an initial public offering of common stock in 1987. The Company is engaged in the development, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industry. Its purpose is to create scientifically proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. At the same time, it is investigating ways to develop new products utilizing First Defense and Nisin technologies. Its product, First Defense, is manufactured from cows' colostrum using its proprietary vaccine and whey protein purification technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. First DefenseÒ is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K99 and coronavirus. During the fourth quarter of 2011, it sold the 11,000,000th dose of First DefenseÒ, since receiving USDA approval of this product in 1991. In 1999, it acquired Wipe OutÒ Dairy Wipes, which is its second source of product sales revenue. That transaction included the purchase of certain equipment, trademarks and a license of intellectual property, including several issued patents, covering the product and rights to develop skin and environmental sanitizing applications of the Nisin technology. Wipe OutÒ Dairy Wipes consist of biodegradable towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking. Nisin is an antibacterial peptide that has been demonstrated in clinical studies to be an effective aid in the reduction of mastitis-causing organisms in dairy cows. First DefenseÒ is generally sold through large, financially strong distributors, which it believes has resulted in minimal bad debt with respect to this product. The Company provides for a 50% account credit for domestic distributors on expired First DefenseÒ product, which has a two-year shelf life resulting in an immaterial amount of returns. The Company's competition in the animal health market includes other biotechnology companies and major animal health companies. In addition to direct competition from oral antibody products, First DefenseÒ also competes for market share against vaccine products that are used to increase the production of antibodies by the dam that can then be transferred through the mother's milk to the calf and against vaccine products that are administered to the newborn calf.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide